These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 26294741

  • 1. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y, Cho H, Hur W, Sim T.
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [Abstract] [Full Text] [Related]

  • 2. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.
    Clin Cancer Res; 2013 May 01; 19(9):2572-83. PubMed ID: 23493349
    [Abstract] [Full Text] [Related]

  • 3. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, Li W, Li J.
    Oncotarget; 2015 Feb 10; 6(4):2009-22. PubMed ID: 25576915
    [Abstract] [Full Text] [Related]

  • 4. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J, Wong CC, Leung KT, Wu F, Zhou Y, Tong JHM, Chan RCK, Li H, Wang Y, Yan H, Liu L, Wu WKK, Chan MWY, Cheng ASL, Yu J, Wong N, Lo KW, To KF, Kang W.
    Oncogene; 2020 Oct 10; 39(43):6647-6663. PubMed ID: 32934314
    [Abstract] [Full Text] [Related]

  • 5. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ.
    Mol Cancer Ther; 2013 May 10; 12(5):632-42. PubMed ID: 23443805
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM, SenthilKumar G, Hu R, Goldstein S, Ong IM, Miller MC, Brennan SR, Kaushik S, Abel L, Nickel KP, Iyer G, Harari PM, Kimple RJ, Baschnagel AM.
    Int J Radiat Oncol Biol Phys; 2020 Jul 15; 107(4):793-803. PubMed ID: 32298810
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR, Kent B, Hillary S, Alam MM, Ma X, Gu X, DiGiovanni J, Nathan CO.
    Mol Carcinog; 2019 Oct 15; 58(10):1715-1725. PubMed ID: 31254372
    [Abstract] [Full Text] [Related]

  • 9. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.
    Delpuech O, Rooney C, Mooney L, Baker D, Shaw R, Dymond M, Wang D, Zhang P, Cross S, Veldman-Jones M, Wilson J, Davies BR, Dry JR, Kilgour E, Smith PD.
    Mol Cancer Ther; 2016 Nov 15; 15(11):2802-2813. PubMed ID: 27550940
    [Abstract] [Full Text] [Related]

  • 10. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC, Choi EK, Shin JS, Moon JH, Hong SW, Lee HR, Kim SM, Jung SA, Lee DH, Jung SH, Lee SH, Kim JE, Kim KP, Hong YS, Suh YA, Jang SJ, Choi EK, Lee JS, Jin DH, Kim TW.
    Mol Cancer Ther; 2015 Nov 15; 14(11):2613-22. PubMed ID: 26351320
    [Abstract] [Full Text] [Related]

  • 11. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T.
    Cancer Res; 2012 Apr 15; 72(8):2045-56. PubMed ID: 22369928
    [Abstract] [Full Text] [Related]

  • 12. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H.
    Cancer Res; 2020 Nov 15; 80(22):4986-4997. PubMed ID: 32973082
    [Abstract] [Full Text] [Related]

  • 13. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR.
    Clin Cancer Res; 2012 Dec 15; 18(24):6658-67. PubMed ID: 23082000
    [Abstract] [Full Text] [Related]

  • 14. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
    SenthilKumar G, Fisher MM, Skiba JH, Miller MC, Brennan SR, Kaushik S, Bradley ST, Longhurst CA, Buehler D, Nickel KP, Iyer G, Kimple RJ, Baschnagel AM.
    Mol Cancer Ther; 2020 Jun 15; 19(6):1255-1265. PubMed ID: 32371583
    [Abstract] [Full Text] [Related]

  • 15. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H, Lu J, Tang J, Chen S, He K, Jiang X, Jiang W, Teng L.
    BMC Cancer; 2017 Mar 14; 17(1):191. PubMed ID: 28292264
    [Abstract] [Full Text] [Related]

  • 16. Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia.
    Khandelwal AR, Rong X, Moore-Medlin T, Ekshyyan O, Abreo F, Gu X, Nathan CA.
    Cancer Prev Res (Phila); 2016 Apr 14; 9(4):296-304. PubMed ID: 26862088
    [Abstract] [Full Text] [Related]

  • 17. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.
    Cancer Chemother Pharmacol; 2013 May 14; 71(5):1315-23. PubMed ID: 23468082
    [Abstract] [Full Text] [Related]

  • 18. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.
    Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.
    Mol Cancer Ther; 2017 Apr 14; 16(4):637-648. PubMed ID: 28119489
    [Abstract] [Full Text] [Related]

  • 19. The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells.
    Na YR, Kim JY, Song CH, Kim M, Do YT, Vo TTL, Choi E, Ha E, Seo JH, Shin SJ.
    Int J Mol Sci; 2021 Oct 06; 22(19):. PubMed ID: 34639155
    [Abstract] [Full Text] [Related]

  • 20. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, Stockman PK, Kilgour E, Landers D.
    Ann Oncol; 2017 Jun 01; 28(6):1316-1324. PubMed ID: 29177434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.